It has been shown that in HR+/HER2+ breast cancer cell xenografts, the combination of HER1 (EGFR) and HER2 blockade with gefitinib, trastuzumab, and pertuzumab in combination with estrogen withdrawal was more effective in suppressing tumor growth than any of these agents alone56. Here, ERBB2 is linked to breast carcinoma.